Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).

PHASE4CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 7, 2024

Study Completion Date

February 6, 2025

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Triamcinolone Hexacetonide 20 MG/ML

JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints

Trial Locations (5)

5021

Haukeland University Hospital, Bergen

9019

University Hospital of North Norway, Tromsø

0424

Oslo University Hospital, Oslo

Unknown

St Olavs Hospital, Trondheim

Stavanger University Hospital, Stavanger

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

lead

Oslo University Hospital

OTHER

NCT04614311 - Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA). | Biotech Hunter | Biotech Hunter